Secondary <i>BRAF</i> -mutated histiocytic/dendritic cell sarcoma transdifferentiated from follicular lymphoma with prolonged response to BRAF/MEK inhibition and subsequent evolution to high-grade B-cell lymphoma
- DOI
- 10.1136/jcp-2026-210638
- Published
- 2026-06-09
- Container
- Journal of Clinical Pathology
- Publisher
- BMJ
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1136/jcp-2026-210638,
title = {Secondary
<i>BRAF</i>
-mutated histiocytic/dendritic cell sarcoma transdifferentiated from follicular lymphoma with prolonged response to BRAF/MEK inhibition and subsequent evolution to high-grade B-cell lymphoma},
author = {Claire Royer-Chardon and Bettina Bisig and Mounir Trimech and Baptiste Guey and Edoardo Missiaglia and Sophie Voruz and Alban Denys and Anne Cairoli and Laurence de Leval},
year = {2026},
journal = {Journal of Clinical Pathology},
doi = {10.1136/jcp-2026-210638},
url = {https://doi.org/10.1136/jcp-2026-210638}
}RIS
TY - JOUR
TI - Secondary
<i>BRAF</i>
-mutated histiocytic/dendritic cell sarcoma transdifferentiated from follicular lymphoma with prolonged response to BRAF/MEK inhibition and subsequent evolution to high-grade B-cell lymphoma
AU - Claire Royer-Chardon
AU - Bettina Bisig
AU - Mounir Trimech
AU - Baptiste Guey
AU - Edoardo Missiaglia
AU - Sophie Voruz
AU - Alban Denys
AU - Anne Cairoli
AU - Laurence de Leval
PY - 2026
JO - Journal of Clinical Pathology
DO - 10.1136/jcp-2026-210638
UR - https://doi.org/10.1136/jcp-2026-210638
ER - APA
Royer-Chardon, C., Bisig, B., Trimech, M., Guey, B., Missiaglia, E., Voruz, S., Denys, A., Cairoli, A., & Leval, L. D. (2026). Secondary <i>BRAF</i> -mutated histiocytic/dendritic cell sarcoma transdifferentiated from follicular lymphoma with prolonged response to BRAF/MEK inhibition and subsequent evolution to high-grade B-cell lymphoma. Journal of Clinical Pathology. https://doi.org/10.1136/jcp-2026-210638
Source records
- crossref · retrieved 2026-09-25T12:37:50.031Z